Evolution of protease inhibitor resistance in human immunodeficiency virus type 1 infected patients failing protease inhibitor monotherapy as second-line therapy in …
JA Thompson, C Kityo, D Dunn, A Hoppe… - Clinical infectious …, 2019 - academic.oup.com
Background Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment
programs in low-income countries often delays detection of treatment failure. The impact of …
programs in low-income countries often delays detection of treatment failure. The impact of …
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy …
JA Thompson, C Kityo, D Dunn, A Hoppe… - … Diseases: an Official …, 2019 - europepmc.org
Background Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment
programs in low-income countries often delays detection of treatment failure. The impact of …
programs in low-income countries often delays detection of treatment failure. The impact of …
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy …
JA Thompson, C Kityo, D Dunn, A Hoppe… - Clinical Infectious …, 2019 - academic.oup.com
Background Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment
programs in low-income countries often delays detection of treatment failure. The impact of …
programs in low-income countries often delays detection of treatment failure. The impact of …
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy …
JA Thompson, C Kityo, D Dunn, A Hoppe… - 2019 - pubmed.ncbi.nlm.nih.gov
Background Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment
programs in low-income countries often delays detection of treatment failure. The impact of …
programs in low-income countries often delays detection of treatment failure. The impact of …
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy …
JA Thompson, C Kityo, D Dunn… - Clinical infectious …, 2018 - researchonline.lshtm.ac.uk
BACKGROUND: Limited viral load (VL) testing in human immunodeficiency virus (HIV)
treatment programs in low-income countries often delays detection of treatment failure. The …
treatment programs in low-income countries often delays detection of treatment failure. The …
Evolution of protease inhibitor resistance in human immunodeficiency virus type 1 infected patients failing protease inhibitor monotherapy as second-line therapy in …
JA Thompson, C Kityo, D Dunn, A Hoppe… - 2019 - cabidigitallibrary.org
Background: Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment
programs in low-income countries often delays detection of treatment failure. The impact of …
programs in low-income countries often delays detection of treatment failure. The impact of …
[PDF][PDF] Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line …
JA Thompson, C Kityo, D Dunn, A Hoppe… - Clinical Infectious …, 2019 - academia.edu
Background. Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment
programs in low-income countries often delays detection of treatment failure. The impact of …
programs in low-income countries often delays detection of treatment failure. The impact of …
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy …
JA Thompson, C Kityo, D Dunn… - Clinical Infectious …, 2019 - search.ebscohost.com
Background Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment
programs in low-income countries often delays detection of treatment failure. The impact of …
programs in low-income countries often delays detection of treatment failure. The impact of …
[PDF][PDF] Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line …
JA Thompson, C Kityo, D Dunn, A Hoppe… - 2018 - researchgate.net
Background. Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment
programs in low-income countries often delays detection of treatment failure. The impact of …
programs in low-income countries often delays detection of treatment failure. The impact of …
[PDF][PDF] Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line …
JA Thompson, C Kityo, D Dunn, A Hoppe… - Clinical Infectious …, 2019 - academia.edu
Background. Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment
programs in low-income countries often delays detection of treatment failure. The impact of …
programs in low-income countries often delays detection of treatment failure. The impact of …